When the Human Genome Project was declared complete back in 2003, there were high expectations set for genomic medicine. However, it has taken over a decade to begin moving from vision to reality. Today, the number of success stories remains relatively small, but they do stretch across the healthcare ecosystem, incorporating the prediction of drug responses, the diagnosis of diseases and the identification of targeted therapies. Stakeholders ranging from patients, healthcare providers and payers, researchers, diagnostic companies, policy-makers, life sciences businesses and governments now believe genomic medicine to be a potential game-changer
What do MDs think about patient engagement? What's the gap between today's healthcare marketplace and the marketplace of the future? What is pathway to patient engagement?
Join us for our 4-part webinar series with the latest real time market intelligence on patient engagement.
Building A Chronic Care Management Program That Can ScaleVSee
Achieving 100% COVID Readiness with Chronic Care Telehealth
Chronically ill patients in the US account for 76% of all physician visits. They are also the most susceptible to COVID and COVID-related illnesses. With COVID variants on the rise, telehealth and remote patient monitoring (RPM) are essential to keeping these patients safe, while providing quality care and improving outcomes.
In addition, studies have shown that remote patient monitoring improves patient self-management and leads to earlier interventions. It can also reduce emergency hospital visits 30%. In 2015 Medicare began reimbursing clinicians for using remote patient monitoring technology to manage chronically ill patients with 2+ chronic conditions with Chronic Care Management (CCM) codes. In more recent years, it also began reimbursing remote patient monitoring (RPM) services for a wider range of patients.
Find out how you can become COVID ready by laying the foundations for a successful telehealth Chronic Care Management program on the next Telehealth Secrets webinar. Join us live with CEO Ajay Gehlot, MD, MBA of CareConnect Health–one of the largest primary care providers in the state of Georgia
How To Go From Telehealth Startup To Telehealth EnterpriseVSee
For more information of the presentation such as recording and transcript, please visit:
https://vsee.com/blog/go-telehealth-startup-telehealth-enterprise/
For other webinars:
https://vsee.com/webinars/
Or join our Linkedin Group: https://www.linkedin.com/groups/Telehealth-Failures-Secrets-Success-13500037/about
Or Join our Facebook Group:
https://www.facebook.com/groups/tfssgroup/?ref=group_cover
Demystifying the Telemedicine Triple Threat: Reimbursement, Licensure & HIPAA...VSee
The three most controversial barriers to telemedicine adoption are payment, physician licensure, patient privacy. This presentation from the TFSS webinar will help you learn how these three areas of telemedicine policy affect your ability to practice and get paid for telemedicine. Our telemedicine law & policy expert, Nathaniel Lacktman, discussed how these policies can affect your bottom line and some best practices for maximizing telemedicine performance.
For more information of the presentation such as recording and transcript, please visit:
https://goo.gl/aeolcF
For other webinars:
https://vsee.com/webinars/
Or join our Linkedin Group: https://www.linkedin.com/groups/Telehealth-Failures-Secrets-Success-13500037/about
Or Join our Facebook Group:
https://www.facebook.com/groups/tfssgroup/?ref=group_cover
Patient Engagement is growing in importance as consumer expectations of healthcare providers change and as portals and other technologies improve. Early studies show affects on outcomes for patient engagement technologies
5 Business Strategies to Grow Your Telehealth EnterpriseVSee
To carry on the discussion in real life, join us at Telehealth and Secrets to Success Conference, Sept 20-22, Silicon Valley:
https://goo.gl/95zHZG
For more information of the presentation such as recording and transcript, please visit: https://vsee.com/blog/5-business-strategies-to-grow-like-zocdoc/
For other webinars:
https://vsee.com/webinars/
Or join our Linkedin Group: https://www.linkedin.com/groups/Telehealth-Failures-Secrets-Success-13500037/about
Or Join our Facebook Group:
https://www.facebook.com/groups/tfssgroup/?ref=group_cover
What do MDs think about patient engagement? What's the gap between today's healthcare marketplace and the marketplace of the future? What is pathway to patient engagement?
Join us for our 4-part webinar series with the latest real time market intelligence on patient engagement.
Building A Chronic Care Management Program That Can ScaleVSee
Achieving 100% COVID Readiness with Chronic Care Telehealth
Chronically ill patients in the US account for 76% of all physician visits. They are also the most susceptible to COVID and COVID-related illnesses. With COVID variants on the rise, telehealth and remote patient monitoring (RPM) are essential to keeping these patients safe, while providing quality care and improving outcomes.
In addition, studies have shown that remote patient monitoring improves patient self-management and leads to earlier interventions. It can also reduce emergency hospital visits 30%. In 2015 Medicare began reimbursing clinicians for using remote patient monitoring technology to manage chronically ill patients with 2+ chronic conditions with Chronic Care Management (CCM) codes. In more recent years, it also began reimbursing remote patient monitoring (RPM) services for a wider range of patients.
Find out how you can become COVID ready by laying the foundations for a successful telehealth Chronic Care Management program on the next Telehealth Secrets webinar. Join us live with CEO Ajay Gehlot, MD, MBA of CareConnect Health–one of the largest primary care providers in the state of Georgia
How To Go From Telehealth Startup To Telehealth EnterpriseVSee
For more information of the presentation such as recording and transcript, please visit:
https://vsee.com/blog/go-telehealth-startup-telehealth-enterprise/
For other webinars:
https://vsee.com/webinars/
Or join our Linkedin Group: https://www.linkedin.com/groups/Telehealth-Failures-Secrets-Success-13500037/about
Or Join our Facebook Group:
https://www.facebook.com/groups/tfssgroup/?ref=group_cover
Demystifying the Telemedicine Triple Threat: Reimbursement, Licensure & HIPAA...VSee
The three most controversial barriers to telemedicine adoption are payment, physician licensure, patient privacy. This presentation from the TFSS webinar will help you learn how these three areas of telemedicine policy affect your ability to practice and get paid for telemedicine. Our telemedicine law & policy expert, Nathaniel Lacktman, discussed how these policies can affect your bottom line and some best practices for maximizing telemedicine performance.
For more information of the presentation such as recording and transcript, please visit:
https://goo.gl/aeolcF
For other webinars:
https://vsee.com/webinars/
Or join our Linkedin Group: https://www.linkedin.com/groups/Telehealth-Failures-Secrets-Success-13500037/about
Or Join our Facebook Group:
https://www.facebook.com/groups/tfssgroup/?ref=group_cover
Patient Engagement is growing in importance as consumer expectations of healthcare providers change and as portals and other technologies improve. Early studies show affects on outcomes for patient engagement technologies
5 Business Strategies to Grow Your Telehealth EnterpriseVSee
To carry on the discussion in real life, join us at Telehealth and Secrets to Success Conference, Sept 20-22, Silicon Valley:
https://goo.gl/95zHZG
For more information of the presentation such as recording and transcript, please visit: https://vsee.com/blog/5-business-strategies-to-grow-like-zocdoc/
For other webinars:
https://vsee.com/webinars/
Or join our Linkedin Group: https://www.linkedin.com/groups/Telehealth-Failures-Secrets-Success-13500037/about
Or Join our Facebook Group:
https://www.facebook.com/groups/tfssgroup/?ref=group_cover
Although highly arguable, and patients being central to healthcare systems, patient engagement is one the most underutilized aspect of the healthcare industry. Patient engagement is a promise of better health outcomes as well as the increasing knowledge and skill of people to manage their and their family members’ health.
The Agile Approach to Patient Journey Marketing Carl Olsen
Patient journeys are one of the hottest topics in health care marketing and with good reason. They can achieve excellent results by directing engagement tactics to where an individual consumer is on the decision-making continuum for elective health care services. By segmenting consumers along the journey, health systems The Agile Approach to Patient Journey Marketing can attain increased utilization, enhanced patient satisfaction and heightened loyalty.
Within the first three months, 479 visitors responded to the one ad UC Health ran on Facebook. Twenty-five percent of visitors signed up for a seminar, took the quiz or downloaded documents from the microsite; and those 120 prospects provided a name, email address and other information that could be used in future consumer engagement initiatives. Seminar registrations increased 4 percent, and the conversion rate for surgery nearly doubled by month three.
This infographic speaks to the challenges Emergency Departments face in caring and following up with the growing population of patients they see, and demonstrates how some EDs are seeing measurable improvements in care, patient satisfaction and efficiency.
Partnering with Patients, Families and Communities for Health: A Global Imper...EngagingPatients
Engagement is an essential tool to improving global health. This report introduces a new framework for engagement to help countries assess current programs and think strategically about future engagement opportunities. It spotlights barriers to engagement and offers concrete examples of effective engagement from around the globe.
OpenNotes: Transparent Clinicians' Notes for Health & IllnessOpenNotes
Sharing clinicians’ notes with patients is a simple idea for health. This presentation can be used to introduce your institution to the benefits of open notes and how to adopt this practice with your patients. It guides you through the OpenNotes study, which sparked a movement towards more transparent notes across the nation.
Creating value through patient support programsSKIM
How do we become more patient-centered as an organization? How do we ensure the patient/caregiver experience is as optimal as possible?
These are the questions that are being poised to healthcare market researchers in today’s healthcare landscape. And typically healthcare market researchers are turning to methods like “patient journeys” and “patient personas” to help bring that patient-centered understanding to the organization. Problem is … in order to be truly patient-centered, you need to take this charge on from the inside out.
Experience, Design and Innovation departments are springing up in all kinds of healthcare organizations intent on facilitating the organizational shift towards patient-centricity. And, unfortunately, market researchers are intentionally not being invited to the table. If history repeats itself, that will soon change though. These Experience, Design and Innovation departments will need the rigor and breadth of method knowledge that market researchers have in order to succeed in the strategic agendas of their work.
This presentation will give market researcher pointers on which skills, methods and mindsets they’ll likely need to adopt if they are hoping to be perceived as a valued contributor to an Experience, Design or Innovation team. In essence, give attendees a blueprint for how to open up a whole new professional opportunity for themselves, with a simple reframe on whom they are and what they do.
mHealth Israel_Innovation reaching the Voice of the Patient_SiemensLevi Shapiro
Innovation reaching the Voice of the Patient, lecture by Christina Triantafyllou, Ph.D, Head of Improving Patient Experience at Siemens Healthineers. Key Sections:
Pushing the boundaries with Innovation
Translate innovation into patient experience
The voice of patients is becoming increasingly important
Improving patient experience
We enable healthcare providers to increase value by Improving patient experience
The biggest levers to optimize the patient diagnostic experience are the three core dimensions: staff, process, and equipment
Steps to deliver outcomes that matter to patients
We enable healthcare providers to increase value by Improving patient experience
Identify the right priorities: What are the factors influencing the patient experience across the continuum of care?
Patient experience during COVID-19
Patients feel uncomfortable to seek care
Five lessons learned so far
Patient experience in times of COVID-19
Patient Journey
Presentation: The Evolving Patient Journey
Presented by: Meredith Ressi, VP, Multichannel Marketing Solutions, Decision Resources Group
Healthcare communications today require an understanding of the complexity of patient decision making and how patients navigate the health system to get the care they need. What are the emerging trends in patient engagement, and how does channel reliance vary along the treatment continuum?
The Patient-Centered Medical Home in the Transformation From Healthcare to He...Paul Grundy
Surgeon General of the Navy VADM Matthew L. Nathan, MC USN
Fortunately, we have a way to address this crisis—the
Patient-Centered Medical Home (PCMH) model launched at Naval Hospital Pensacola and Walter Reed National Military Medical Center, Bethesda, Maryland (formerly the National Naval Medical Center) in 2008. It is now being implemented throughout the Military Health System (MHS) and carries great promise. It provides the clinical framework we need to meet our strategic objectives in terms of quality of care, impact on costs, population health, and readiness. One of the most significant benefits of the team-based, collaborative approach is that it allows us to embed within a primary care environment the psychologists, nutritionists, tobacco cessation specialists, mind-body medicine therapists, and health educators our patients need in order to develop and maintain mindful, healthy behaviors—along with the “mental armor,” our active duty military personnel need to increase their operational effectiveness and their resiliency in bouncing back from stressful situations. As we move ahead with this more comprehensive approach to health, we can begin to better address so many of our patients for whom we can find no specific reason for pain and discomfort. The PCMH model also provides a positive impact on our costs. Early data reporting from the PCMH clinics at Bethesda show reduced visits to the emergency room, lowered pharmacy costs, and significant per beneficiary per year savings and improved Healthcare Effectiveness Data and Information Set metrics, access, and patient satisfaction and trust. These positive impacts on the bottom line can be applied directly to improved costs or toward the reallocation of resources from reimbursing those who are sick to the population health-based programs that can make and keep our patients healthy.More significant, however, the PCMH environment allows us to go beyond mere collaboration and to a much more proactive approach to managing our patient populations. It is within the context of the medical home that we can begin to surround our patients with the tools and resources they need to move them from health care to health.
A slide series to learn and appreciate the importance and the potential of Personalized/Individualized Genomic Medicine. It briefly goes through the idea of biotechnology and the advancements we have made in biology and technology. A series of applications for genomic medicine is then explored, not failing to mention the challenges we have to overcome as well, for the next medical revolution.
A case for personalized medicine is presented.
Although highly arguable, and patients being central to healthcare systems, patient engagement is one the most underutilized aspect of the healthcare industry. Patient engagement is a promise of better health outcomes as well as the increasing knowledge and skill of people to manage their and their family members’ health.
The Agile Approach to Patient Journey Marketing Carl Olsen
Patient journeys are one of the hottest topics in health care marketing and with good reason. They can achieve excellent results by directing engagement tactics to where an individual consumer is on the decision-making continuum for elective health care services. By segmenting consumers along the journey, health systems The Agile Approach to Patient Journey Marketing can attain increased utilization, enhanced patient satisfaction and heightened loyalty.
Within the first three months, 479 visitors responded to the one ad UC Health ran on Facebook. Twenty-five percent of visitors signed up for a seminar, took the quiz or downloaded documents from the microsite; and those 120 prospects provided a name, email address and other information that could be used in future consumer engagement initiatives. Seminar registrations increased 4 percent, and the conversion rate for surgery nearly doubled by month three.
This infographic speaks to the challenges Emergency Departments face in caring and following up with the growing population of patients they see, and demonstrates how some EDs are seeing measurable improvements in care, patient satisfaction and efficiency.
Partnering with Patients, Families and Communities for Health: A Global Imper...EngagingPatients
Engagement is an essential tool to improving global health. This report introduces a new framework for engagement to help countries assess current programs and think strategically about future engagement opportunities. It spotlights barriers to engagement and offers concrete examples of effective engagement from around the globe.
OpenNotes: Transparent Clinicians' Notes for Health & IllnessOpenNotes
Sharing clinicians’ notes with patients is a simple idea for health. This presentation can be used to introduce your institution to the benefits of open notes and how to adopt this practice with your patients. It guides you through the OpenNotes study, which sparked a movement towards more transparent notes across the nation.
Creating value through patient support programsSKIM
How do we become more patient-centered as an organization? How do we ensure the patient/caregiver experience is as optimal as possible?
These are the questions that are being poised to healthcare market researchers in today’s healthcare landscape. And typically healthcare market researchers are turning to methods like “patient journeys” and “patient personas” to help bring that patient-centered understanding to the organization. Problem is … in order to be truly patient-centered, you need to take this charge on from the inside out.
Experience, Design and Innovation departments are springing up in all kinds of healthcare organizations intent on facilitating the organizational shift towards patient-centricity. And, unfortunately, market researchers are intentionally not being invited to the table. If history repeats itself, that will soon change though. These Experience, Design and Innovation departments will need the rigor and breadth of method knowledge that market researchers have in order to succeed in the strategic agendas of their work.
This presentation will give market researcher pointers on which skills, methods and mindsets they’ll likely need to adopt if they are hoping to be perceived as a valued contributor to an Experience, Design or Innovation team. In essence, give attendees a blueprint for how to open up a whole new professional opportunity for themselves, with a simple reframe on whom they are and what they do.
mHealth Israel_Innovation reaching the Voice of the Patient_SiemensLevi Shapiro
Innovation reaching the Voice of the Patient, lecture by Christina Triantafyllou, Ph.D, Head of Improving Patient Experience at Siemens Healthineers. Key Sections:
Pushing the boundaries with Innovation
Translate innovation into patient experience
The voice of patients is becoming increasingly important
Improving patient experience
We enable healthcare providers to increase value by Improving patient experience
The biggest levers to optimize the patient diagnostic experience are the three core dimensions: staff, process, and equipment
Steps to deliver outcomes that matter to patients
We enable healthcare providers to increase value by Improving patient experience
Identify the right priorities: What are the factors influencing the patient experience across the continuum of care?
Patient experience during COVID-19
Patients feel uncomfortable to seek care
Five lessons learned so far
Patient experience in times of COVID-19
Patient Journey
Presentation: The Evolving Patient Journey
Presented by: Meredith Ressi, VP, Multichannel Marketing Solutions, Decision Resources Group
Healthcare communications today require an understanding of the complexity of patient decision making and how patients navigate the health system to get the care they need. What are the emerging trends in patient engagement, and how does channel reliance vary along the treatment continuum?
The Patient-Centered Medical Home in the Transformation From Healthcare to He...Paul Grundy
Surgeon General of the Navy VADM Matthew L. Nathan, MC USN
Fortunately, we have a way to address this crisis—the
Patient-Centered Medical Home (PCMH) model launched at Naval Hospital Pensacola and Walter Reed National Military Medical Center, Bethesda, Maryland (formerly the National Naval Medical Center) in 2008. It is now being implemented throughout the Military Health System (MHS) and carries great promise. It provides the clinical framework we need to meet our strategic objectives in terms of quality of care, impact on costs, population health, and readiness. One of the most significant benefits of the team-based, collaborative approach is that it allows us to embed within a primary care environment the psychologists, nutritionists, tobacco cessation specialists, mind-body medicine therapists, and health educators our patients need in order to develop and maintain mindful, healthy behaviors—along with the “mental armor,” our active duty military personnel need to increase their operational effectiveness and their resiliency in bouncing back from stressful situations. As we move ahead with this more comprehensive approach to health, we can begin to better address so many of our patients for whom we can find no specific reason for pain and discomfort. The PCMH model also provides a positive impact on our costs. Early data reporting from the PCMH clinics at Bethesda show reduced visits to the emergency room, lowered pharmacy costs, and significant per beneficiary per year savings and improved Healthcare Effectiveness Data and Information Set metrics, access, and patient satisfaction and trust. These positive impacts on the bottom line can be applied directly to improved costs or toward the reallocation of resources from reimbursing those who are sick to the population health-based programs that can make and keep our patients healthy.More significant, however, the PCMH environment allows us to go beyond mere collaboration and to a much more proactive approach to managing our patient populations. It is within the context of the medical home that we can begin to surround our patients with the tools and resources they need to move them from health care to health.
A slide series to learn and appreciate the importance and the potential of Personalized/Individualized Genomic Medicine. It briefly goes through the idea of biotechnology and the advancements we have made in biology and technology. A series of applications for genomic medicine is then explored, not failing to mention the challenges we have to overcome as well, for the next medical revolution.
A case for personalized medicine is presented.
Transforming the NHS through genomic and personalised medicine, pop up uni, 1...NHS England
Expo is the most significant annual health and social care event in the calendar, uniting more NHS and care leaders, commissioners, clinicians, voluntary sector partners, innovators and media than any other health and care event.
Expo 15 returned to Manchester and was hosted once again by NHS England. Around 5000 people a day from health and care, the voluntary sector, local government, and industry joined together at Manchester Central Convention Centre for two packed days of speakers, workshops, exhibitions and professional development.
This year, Expo was more relevant and engaging than ever before, happening within the first 100 days of the new Government, and almost 12 months after the publication of the NHS Five Year Forward View. It was also a great opportunity to check on and learn from the progress of Greater Manchester as the area prepares to take over a £6 billion devolved health and social care budget, pledging to integrate hospital, community, primary and social care and vastly improve health and well-being.
More information is available online: www.expo.nhs.uk
Towards Digitally Enabled Genomic Medicine: the Patient of The FutureLarry Smarr
12.02.22
Invited Speaker
Hacking Life
TTI/Vanguard Conference
Title: Towards Digitally Enabled Genomic Medicine: the Patient of The Future
San Jose, CA
Today, a mix of influences - including innovation in biology and technology, market demand and consumerism - is furthering a genomic medicine evolution that crosses industries.
To benefit from the far-reaching industry transformation that has begun, forward-thinking executives can: verify that genomic medicine is part of their enterprise vision and strategy; assess and plan to fill existing and future skill gaps; and look closely at how and when partnering will help their organizations succeed in meeting stakeholder needs.
Genomics England and the power of DNA databis_foresight
Presentation by Sir Mark Walport at the Wired Health Conference on 29 April 2014.
Read a report of the presentation at: http://www.wired.co.uk/news/archive/2014-04/29/sir-mark-walport
#wiredhealth
Big Data and Genomic Medicine by Corey NislowKnome_Inc
View the webinar at: http://www.knome.com/webinar-big-data-genomic-medicine. This presentation covers an overview of genomic medicine, requirements and challenges of next-generation sequencing, bottlenecks to broader healthcare adoption, and why “we want to sequence everyone.”
As most NHS Trust’s advance in their commitment to deliver high quality services such as those illustrated by the Service Improvement Programme, it is essential the organisation is able to support good quality services through well informed decision making for services users and carers.
This whitepaper looks at ways in which Trusts can improve how they share knowledge and work collaboratively towards the main goal; quality patient care.
whole genome analysis
history
needs
steps involved
human genome data
NGS
pyrosequencing
illumina
SOLiD
Ion torrent
PacBio
applications
problems
benefits
As we understand more about the human body and how it functions and degrades, biotechnology will progress. This is only the beginning, but when new technology and procedures become accessible, certain themes will start to develop in biopharma trends.
Companies, organizations, and research institutes that are committed to bettering the lives of living organisms fall under the umbrella term known as the life sciences industry. Pharmaceuticals, biotechnology, environmental sciences, biomedicine, nutraceuticals, neurology, cell biology, biophysics, and a lot of other subfields might be classified as some of the different subfields that fall under the umbrella of the life sciences business.
Welcome to the age of cognitive computing: where intelligent machines have
moved from the realms of science fiction to the present day. This groundbreaking
technology is driving advanced discoveries and allowing improved decision-making –
resulting in better patient care
Genome sequencing technology available today can accurately sequence a whole genome from an individual’s test sample for a surprisingly low cost.
As a result, the adoption of this technology is rapidly expanding as medical centers around the world embrace its utility in informing healthcare decisions—an emerging reality of personalized medicine.
Make DNA data actionable - Festival of Genomics London 2018Omar Fogliadini
Consumers are looking for more control over their own health and healthcare, and with the advent of affordable genetic testing there are new avenues for personalised treatment and precision medicine.
As consumer tests come to the fore and patients arrive at their doctor appointments brandishing their own genetic data and full of questions and opinions. Concerns still remain that patients – and not a few physicians – don't always understand what the genetic results mean and just what to do about them. But as consumers get more comfortable with those companies' offerings, the visits with their doctors are often getting more complex.
With the increased use of the Internet for medical information, consumers have become medical consumers not just patients This has created a change in the doctor/patient relationship as individuals become more knowledgeable about their own health and want more control over their personal information and treatment decisions. Physicians, meanwhile, are concerned about giving patients too much access to information they may not properly understand. Even many doctors aren't well-trained in the clinical implications of genetics and genomics.
The CMO’s Generation Genome report is focused on the need for the UK to maintain its presence as a world leader in genomic medicine. It presented a vision of genomics being integrated into the NHS within the next 5 years.
The “vast majority” of NHS doctors are “not up to speed” with modern genetic techniques that can transform patients’ chances.
GENOMIC INTELLIGENCE
Suisse Life Science specialiSes in making DNA data useful for population health management.
Using our flagship Scienceof[DNA]f(x) technology, Suisse Life Science Group can provide you with an evidence-based lifestyle behavioural medicine dynamic system based on the associated genetic variants supported by literature citations for health, wellness or chronic diseases, and customised around your needs.
What used to take weeks of painstaking manual curation can now be completed in days.
PERSONALISED HEALTH TECHNOLOGY FOR GENOMIC COMPANIES OR CUSTOM APPLICATIONS
We help companies by providing a comprehensive nutritional, metabolic and lifestyle analysis and management program that includes nutrition intake and lifestyle monitoring, followed by a personalised nutritional, chronic disease prevention and sport recommendations, tailored for the user, informed on their biomarkers but updated - in real-time - with life data from consumer devices (smartphones, wearables…).
Ready-to-market technology.
Ask for a demo at info@suisselifescience.com
Strand featured in CIO Review: Pharma and Life Science Special edition - July 2014
Strand Genomics Inc recognised by CIO Review as one among 20 most promising Tech solution providers to Pharma and Life science industry 2014
The word genome can refer specifically to the DNA in the nucleus of a cell, but it can also refer to the genome of organelles
that contain their own DNA. Additionally, the genome can include
non-chromosomal genetic elements - viruses, plasmids and transposons. When the genome of a sexually reproducing organism is
said to be sequenced, it is typically understood that one haploid set
of autosomes and one of each type of sex chromosome has been sequenced, which together describe the genomes of both sexes. The
term “genomic sequence” can include a mosaic of data collected
from the chromosomes of different individuals, so this sequence is
representative of the genetic material of a given species. The study
of the general properties of the genome, their evolution and the
connection with the phenotype is called genomics, and thus differs
from genetics, which in principle studies the properties of a single
gene or group of genes.
Use of Genetic Databases to Advance Diagnostic Test DevelopmentEMMAIntl
In December 2018, the U.S. Food and Drug Administration formally recognized a public database that contains information about genes, genetic variants, and their relationship to disease. This blog discusses the motivation for creating such public databases and the implications for developers of genetic tests...
Eco friendly: The emerging life sciences ecosystem Heather Fraser
Pharma and life sciences collaborations will be taken to a whole new level as emerging ecosystems shake up traditional practices. The emphasis on operations for mutual self-interest and broader benefit will spur openness to innovate and the free flow of ideas and resources.
After the Human Genome Project was completed in 2003, early successes in genomic medicine fell short of the initial
high expectations. But today, a potent mix of influences — including innovation in biology and technology, market demand and consumerism — is furthering an evolution that crosses industries. Healthcare providers can now personalize care plans thanks to lower sequencing
costs that allow genomic data to be combined with electronic health data. Life sciences companies can develop targeted therapies that prevent and alleviate disease symptoms. To capitalize on new advances
in science, cognitive computing, analytics and drug discovery, senior leaders across the ecosystem should act quickly to: make genomic medicine a key component of enterprise strategy; address relevant skill gaps; and determine how partnering can bolster critical capabilities.
The convergence of separate health systems has led to
a great increase in data, which some organisations are
struggling to get to grips with. Harnessing analytic tools
and sharing knowledge is the best way forward
Health device makers, to date, have primarily targeted consumers who are either fitness focused or chronically ill. But between these two extremes sits a large, fragmented and often overlooked population who seek better information to effectively manage their health. Our research suggests that successful solution providers will approach this market opportunity as an ecosystem of partners – with an integrated solution that extends beyond the device itself. By plugging the information gap for these consumers, solution providers can help fuel healthcare innovation.
IBM_analytics across the healthcare ecosystem Heather Fraser
Analytics is a key enabler for life sciences and healthcare organizations to create better outcomes for patients, customers and other stakeholders across the entire healthcare ecosystem. While almost two-thirds of organizations across the healthcare ecosystem have analytics strategies in place, our research shows that only a fifth are driving analytics adoption across the enterprise. The key barriers are a lack of data management capabilities and skilled analysts, as well as poor organizational change management. To develop and translate insights into actions that enhance outcomes, organizations will need to collaborate across an expanding ecosystem.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
2. 48 www.samedanltd.com
technological mix that is pushing
genomics forward.This convergence has
led to near-instant dissemination of fresh
discoveries,as well as new forms of social
and scientific collaboration.
Regulatory Role
As genomic medicine continues to
proliferate,the importance of a solid
privacy,ethical and legal framework to
support the complexity of the tool will
become vital.
To date,the regulator’s role in genomics
has primarily been concerned with
protecting consumers from a privacy
and legal stand-point. In the US,The
Genetic Information Nondiscrimination
Act of 2008 protects citizens from
discrimination based on the results
derived from a genetic test. Other
privacy considerations include informed
consent (for both genetic testing and
research purposes) and confidentiality,
such as anonymising data.
Social and ethical aspects of genomic
medicine will also require further
attention and clarification.In the UK,a
voluntary agreement – the Concordat and
Moratorium on Genetics and Insurance –
exists between the government and the
Association of British Insurers to ensure
that individuals are not debarred from
health or life insurance as a result
of genetic testing (8).
In Europe, the EMA has recently
distributed a consultation paper intended
to form the basis of good genomics
biomarker practices.With this guidance,
the EMA aims to enhance transparency,
consistency,reproducibility and cross-
validation between genomic-driven
and drug identifications,and can also
provide more specificity for product
development.Innovative clinical trials
can lead to accelerated approval of
targeted drugs that meet the criteria of
efficacy,utilisation and cost-effectiveness.
Technological innovations – such as
high-performance computing platforms
– are keeping pace with that of gene
discovery and whole-genome sequencing
cost and speed.Furthermore,cognitive
computing allows a system to make
use of natural language processing and
machine learning to ingest large and ever-
expanding data volumes.It can be trained
to provide – with high accuracy and
speed – advice that is otherwise manual,
time-consuming and prone to missing
available evidence. New awareness,
understanding and clarification will
set the stage for the discovery and
generation of fresh ideas.
The New York Genome Center (NYGC)
and IBM are partnering in a first-of-a-kind
programme to accelerate personalised,
life-saving treatment for cancer patients.
Together,both organisations will test
a unique Watson cognitive technology
prototype, designed specifically for
genomic research as a tool to help
oncologists deliver more individualised
care to cancer patients.
NYGC and its medical partner institutions
plan to initially evaluate the Watson
technology’s ability to help oncologists
develop more personalised care to
glioblastoma sufferers:an aggressive
and malignant brain cancer that kills
more than 13,000 people in the US each
year.This initiative aims to speed up
the process of analysing genetic data,
along with comprehensive biomedical
literature and drug databases,in order to
unlock insights that will help clinicians
bring the promise of genomic medicine
to their patients (5).
Such studies enable discovery by
integrating information related to
problems that previously required large
amounts of manual work,and whose
solution attempts were potentially prone
to missing evidence.The implications
of improving innovation are highly
relevant for the pharma industry as it
seeks ways to reduce the time and cost
of developing drugs that are efficacious
and highly targeted.
Consumerism
The growing commercialisation of
genomics is evident in the increased
uptake of direct-to-consumer testing,
as well as in more recent regulatory
concerns and recommendations
about such technologies.These
have led to genomics attracting
new media attention and becoming
more‘mainstream’.
The gene company 23andme
launched their genetic service in
the UK in December 2014 – despite
violating regulatory codes for medical
devices in the US.They chose the UK
as it is a genomics world leader, and
because the Medicine and Healthcare
Products Regulatory Agency does not
consider their personal genome testing
kit – designed to give details about a
person’s health risks based on their
DNA – to be a device (6).
Market Voice
Today,there is a demand for novel ways
of impacting health outcomes through
innovative therapies.In the industry,
there is an increased expectation and
market demand for targeted drugs and
tests that can offer significant benefits
quickly,as opposed to incremental
advantages delivered over time.
Genomics is also converging with social
media,as evidenced by the sharing of
health experiences and questions online.
One example of this is PatientsLikeMe.
com,a health data-sharing platform
including blog videos on topics such
as‘The future of the personal genome’
(7).Social media tools can also be used
for crowd-sourcing,which can provide
supplementary data in scientific and
medical research.
Improved computing power, imaging
capability, the use of wireless sensors
and the plethora of accessible digital
health information are all part of the
In a recent global survey of 750 industry
executives from the life sciences industry,
20% said that the advancement of
personalised medicine (including genomics
and proteomics) was helping to stimulate
innovation in the industry, while a further
36% agreed that cognitive computing was
a key factor (5).
Genomic Medecine’s
Role in Innovation
3. www.samedanltd.com 49
conditions, 21 April 2014. Visit: http://
ghr.nlm.nih.gov/handbook/hgp/genome
5. Life Technologies, Ion AmpliSeq™
comprehensive cancer panel. Visit:
www.lifetechnologies.com/order/
catalog/product/4477685
6. The New York Genome Center and IBM
Watson Group announce collaboration
to advance genomic medicine, March
2014. Visit: www.nygenome.org/news/
in-the-media
7. Reuters, Gene company 23andme
launches in UK after US regulatory
hurdle, 2 December 2014. Visit: www.
reuters.com/article/2014/12/02/
us-health-genetics-britain-23andme-
iduskcn0jg0oy20141202
8. The future of the personal genome, The
Value of Openness by patientslikeme®
,
21 May 2012. Visit: http://blog.
patientslikeme.com/2012/05/21/the-
future-of-the-personal-genome
9. PHG Foundation, UK moratorium
on use of genetic tests by insurers
extended, January 2015. Visit: www.
phgfoundation.org/news/16536/?utm_
source=feedburner&utm_medium
=feed&utm_campaign=feed%3a+
phgfoundation_articles+%28articles+fro
m+the+phg+foundation+newsletter%29
10. EMA, European Medicines Agency
looks to stimulate better use of
genomic data and biomarkers in
medicines development and safety
monitoring, 4 August 2014. Visit:
www.ema.europa.eu/ema/index.
jsp?curl=pages/news_and_events/
news/2014/08/news_detail_002154.
jsp&mid=wc0b01ac058004d5c1
studies,and ultimately stimulate better
use of genomic data and biomarkers
in medicines development and safety
monitoring (9).
Becoming a Reality?
A four-year 100,000 Genomes Project,
initiated by Genomics England,aims
to help turn scientific discoveries about
DNA and its actions into a potentially
life-saving reality for patients through
targeted treatments (10).In early 2014,
11 genomics medicines centres across
England began collecting DNA samples,
with the project due to be completed in
2017.The NHS now has the unique ability
to link a person’s genome data with their
complete medical records,and then
replicate this at scale.
The primary beneficiaries of this project
will be patients with rare diseases or
cancer – but it has also been recognised
that there will significant economic
reward from creating a new industry
based on genomics,in which pharma
plays a pivotal role.
Industry Transformation
Genomic medicine can form the basis of
the development of innovative clinical
trial protocols,as well as the search for
a novel group of precision treatments
focusing on the prevention of disease or
alleviating symptoms.For this to happen,
senior executives of pharma companies
will need to capitalise on new advances
in science,cognitive computing,analytics
and drug discovery,and make genomic
medicine a key component of their
enterprise strategy.Securing a place
in the future genomic medicine
environment will be a key step in the
industry’s transformational journey.
References
1. Pai A, Koyama T and Lee L, The
evolving promise of genomic
medicine: How advanced technologies
are transforming healthcare and
life sciences, IBM Institute for
Business Value, June 2014. Visit:
www-935.ibm.com/services/us/gbs/
thoughtleadership/genomicmedicine
2. Lefever G, Pesanello M, Fraser H and
Taurman L, Fade or flourish? Rethinking
the role of life sciences companies
in the healthcare ecosystem, IBM
Institute for Business Value, August
2011. Visit: www-935.ibm.com/
services/us/gbs/thoughtleadership/ibv-
lifesciences-fade-flourish.html
3. IBM Institute for Business Value survey,
Innovation in the life sciences industry.
Due to be published mid-April 2015 –
contact the author for further details
4. US National Library of Medicine,
National Institutes of Health, What is
a genome? Genetics home reference:
Your guide to understanding genetic
About the author
Heather Fraser
has over 30 years’
experience in
the life sciences
and healthcare
sectors, working
across community
pharmacy, the pharma industry and in
consultancy. She is currently Global
Leader for healthcare and life sciences
in IBM’s Institute for Business Value,
where she develops strategies on
industry-related business issues.
Email: hfraser@uk.ibm.com
Clarification
Clarify the significance of
new ideas through a series
of deeper enquiries
Understanding
Gain a deeper understanding
of the meaning of relationships
and their implications
Awareness
Gain awareness of all
domain-relevant concepts and
individual relationships that
impact a researcher
Figure 1: Discovery and new ideas creation in the life sciences industry